Phase 2 N=296 Therapy for Pediatric Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Phase 2 N=23 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Phase 2 N=80 Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Hodgkin's Lymphoma
Primary: 3-year Event-Free Survival Probability — 0.887 probability — p=0.9970
Phase 2 N=42 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Phase 2 N=34 Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) as Determined by Local Investigator — 32.1 Percentage of participants
N/A N=1,598 B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
Classical Hodgkin Lymphoma · Relapsed or Refractory Classical Hodgkin Lymphoma
Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months
Phase 2 N=72 A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Hodgkin Disease
Primary: Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1 — 92.9 Percent of participants
Phase 3 N=166 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma · Stage III Childhood Hodgkin Lymphoma · Stage IV Childhood Hodgkin Lymphoma
Primary: Second-event-free Survival — 0.91 Probability of survival
Phase 3 N=287 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
Childhood Favorable Prognosis Hodgkin Lymphoma · Childhood Lymphocyte Depletion Hodgkin Lymphoma · Childhood Mixed Cellularity Hodgkin Lymphoma
Primary: Event Free Survival Without Receiving Radiation Therapy (EFSnoRT). — 0.49 Probability of survival
Phase 2 N=34 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Complete Response Rate — 34 Participants
Phase 2 N=46 S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Phase 3 N=1,734 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma · Childhood Mixed Cellularity Classical Hodgkin Lymphoma · Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Primary: Event-free Survival — 0.89; 0.87; 0.84; 0.87 Probability of survival
Phase 2 N=39 Rituximab in Treating Patients With Hodgkin's Lymphoma
Lymphoma · Hodgkin Lymphoma (Category) · Nodular Lymphocyte Predominant Hodgkin Lymphoma
Primary: Progression-free Survival (PFS) — 18 participants
Phase 2 N=348 Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL) · Primary Mediastinal Large B-cell Lymphoma · Burkitt Lymphoma
Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Phase 2 N=46 Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma · Recurrent Childhood Hodgkin Lymphoma · Refractory Childhood Hodgkin Lymphoma
Primary: Maximum Tolerated Dose (MTD) for Brentuximab Vedotin — 1.8 mg/kg
Phase 2 N=37 Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk
Hodgkin Lymphoma
Primary: Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of Nivolumab as Maintenance Therapy — 33 Participants
Phase 2 N=18 Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
EBV-Related Post-Transplant Lymphoproliferative Disorder · Monomorphic Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder
Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…
Phase 2 N=80 Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
Hodgkin Disease
Primary: Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. — 21.0; 28.6 percentage of participants
Phase 2 N=75 PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
Hodgkin Lymphoma, Adult
Primary: ORR Assess by IRC — 76.0 percentage
Phase 2 N=96 Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Non-Hodgkin's Lymphoma
Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients
Phase 3 N=1,895 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
T Acute Lymphoblastic Leukemia · T Lymphoblastic Lymphoma
Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability
Phase 1 N=12 Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Leukemia, Lymphocytic · Lymphoblastic Lymphoma · T-cell Lymphoma
Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants
Phase 2 N=53 Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Lymphoma
Primary: 3 Year Progression-Free Survival Rate — 30 percentage of participants
Phase 2 N=129 Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
Classical Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) as Assessed by the Investigator Based on Cheson Response Criteria — 5; 30; 71; 14 Participants
Phase 2 N=68 Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas
Non-Hodgkin's Lymphoma
Primary: Percentage of Patients With Complete Response to the Combination Chemotherapy — 75.0; 23.0 Percentage of participants
Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Phase 3 N=393 Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
Lymphoma
Primary: Event-free Survival — 88; 82; 80; 63 percentage of particpants — p=.97
Phase 2 N=31 Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Low-Grade Lymphoma
Primary: Number of Participants With Objective Response — 1; 2; 14; 6 Participants